About US
Contact us
-
EpiPen litigation comes back to haunt Teva a decade after initial settlementsBetween opioid litigation, price fixing claims, generic carve-out feuds—and, now, a class-action lawsuit alleging copycat launch shenanigans—Teva Pharmaceutical has certainly kept the courts busy in2022/12/5
-
GSK, Sanofi, Takeda sign with Singapore partnership to advance biologic manufacturingGlobal pharma giants GSK, Sanofi and Takeda signed on with with apartnership of agenciesto advance biologic manufacturing in Singapore. The production partnership is through the Biologics2022/12/5
-
AstraZeneca sells US plant to Resilience, forging manufacturing pact in the processA new era is dawning at an AstraZeneca facility that once formed part of the company’s U.S. COVID-19 vaccine production network. AstraZeneca has locked in asaleof its site in West Chester, Ohio, t2022/12/1
-
Amgen, J&J and Sanofi size up Horizon as Big Pharma renews interest in rare disease M&AAs Big Pharma companies face growing competitive pressures for their existing businesses, they’ve been increasingly drawn to rare disease M&A. That trend appears to be intact with some new dealma2022/12/1
-
NMPA Held the Work Conference on Promoting Foreign Trade...On November 15, 2022, in order to thoroughly implement the decisions and plans of the CPC Central Committee and the State Council, and focus on the new missions and requirements proposed in the Repor2022/11/29
-
ScPharmaceuticals prices $50M offering to fund commercialization of on-body infusorScPharmaceuticals hassecuredfunding for commercialization of its recently approved on-body infusor, pricing a $50 million public offering ahead of the planned launch of the product early next year. L2022/11/24
-
Merck's Keytruda tees up BMS stomach cancer fight with new trial winYears after Merck & Co.'s Keytruda failed to move the needle in newly diagnosed stomach cancer bearing the PD-L1 biomarker, the company has come back with a win, this time for tumorsregardless of2022/11/24
-
Shionogi's COVID-19 antiviral nabs Japanese approval to rival drugs from Pfizer, MerckAs the fight against COVID-19 rolls on, regulators in Japan have bestowed a green light on the country's first homegrown antiviral. The win goes to local drugmaker Shionogi, which hasclinchedan em2022/11/22
-
'Monopoly' allowed Bristol Myers and generics makers to 'steal' from Revlimid purchasers, lawsuit saysThe courtroom drama surrounding Bristol Myers Squibb and its subsidiary Celgene over their efforts to restrict competition for lymphoma drug Revlimid has raged for more than a decade. And2022/11/22
-
FDA moves to boost access to overdose reversal med with preliminary over-the-counter endorsementReady access to opioid antagonists such as naloxone can make all the difference during an overdose. Now, the FDA is chipping away at one of the chief impediments keeping the potentially lifesaving dr2022/11/17